FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4231945484> ?p ?o ?g. }

• W4231945484 endingPage "2520" @default.
• W4231945484 startingPage "2520" @default.
• W4231945484 abstract "2520 Background: Active immunotherapy of FL is a promising therapeutic strategy. Anti-idiotype (Id) antibody and T-cell responses to Id-KLH have been correlated with responses in patients with FL. In a phase II trial, we evaluated the efficacy of Id-KLH vaccination in patients with FL, after cytoreduction with rituximab and during B-lymphopenia. Anti-Id responses were measured and the TTP was compared to historical data for rituximab alone. Methods: Pts with gr 1,2 FL who were treatment naïve; relapsed/refractory to chemo or relapsed after rituximab were eligible. Rituximab (375mg/m2 weekly x4) was followed by response assessment at wk10. Pts with at least SD (CR/PR/SD) started Id-KLH (1 mg s.q. monthly x 6) 12 wks after the first dose of rituximab. GM-CSF 250 mcg was given s.q. at the Id-KLH injection site on days 1–4. Pts with at least SD after 6 doses of Id-KLH could continue receiving the immunotherapy until progression. 123 pts were biopsied and 95 were eligible. Prior trerapy (in 60 of 95) was chemo and rituximab (31) chemotherapy alone (23) or rituximab alone (6). Id-KLH was successfully manufactured in 100% of eligible pts. All eligible pts have received rituximab and 58 pts have begun Id-KLH. Results: 36 patients (all previously treated) have a minimum of 6 months follow-up from first rituximab dose and are included in this preliminary analysis. 5 pts progressed after rituximab and did not receive Id-KLH. Robust T-cell responses to both Id and KLH were observed (3 of 3 pts). Anti-KLH antibody responses were seen in 2 of 10 pts and were delayed until B-cell recovery. 85% of the Id-KLH treated patients were without disease progression after a median of 9.7 months follow-up, compared with 56% of historical controls treated with rituximab alone (Witzig 2002 JCO 20:2453). Adverse events were infrequent with injection site reaction being most common. Conclusions: Id-KLH induces immune responses even after rituximab mediated B-cell depletion in FL patients. Preliminary data suggest that Id-KLH may prolong TTP after rituximab therapy and this strategy will be tested in a randomized phase III trial. No significant financial relationships to disclose." @default.
• W4231945484 created "2022-05-12" @default.
• W4231945484 creator A5014559542 @default.
• W4231945484 creator A5038349333 @default.
• W4231945484 creator A5041556111 @default.
• W4231945484 creator A5044195077 @default.
• W4231945484 creator A5054953103 @default.
• W4231945484 creator A5055647074 @default.
• W4231945484 creator A5060718239 @default.
• W4231945484 creator A5065917441 @default.
• W4231945484 creator A5087064759 @default.
• W4231945484 creator A5091002849 @default.
• W4231945484 date "2004-07-15" @default.
• W4231945484 modified "2023-09-26" @default.
• W4231945484 title "Successful anti-Id T-cell responses to Id-KLH immunotherapy in B-cell depleted patients with follicular lymphoma (FL) may prolong TTP after rituximab: Phase II trial of FavId" @default.
• W4231945484 doi "https://doi.org/10.1200/jco.2004.22.14_suppl.2520" @default.
• W4231945484 hasPublicationYear "2004" @default.
• W4231945484 type Work @default.
• W4231945484 citedByCount "0" @default.
• W4231945484 crossrefType "journal-article" @default.
• W4231945484 hasAuthorship W4231945484A5014559542 @default.
• W4231945484 hasAuthorship W4231945484A5038349333 @default.
• W4231945484 hasAuthorship W4231945484A5041556111 @default.
• W4231945484 hasAuthorship W4231945484A5044195077 @default.
• W4231945484 hasAuthorship W4231945484A5054953103 @default.
• W4231945484 hasAuthorship W4231945484A5055647074 @default.
• W4231945484 hasAuthorship W4231945484A5060718239 @default.
• W4231945484 hasAuthorship W4231945484A5065917441 @default.
• W4231945484 hasAuthorship W4231945484A5087064759 @default.
• W4231945484 hasAuthorship W4231945484A5091002849 @default.
• W4231945484 hasConcept C121332964 @default.
• W4231945484 hasConcept C121608353 @default.
• W4231945484 hasConcept C126322002 @default.
• W4231945484 hasConcept C142424586 @default.
• W4231945484 hasConcept C143998085 @default.
• W4231945484 hasConcept C203014093 @default.
• W4231945484 hasConcept C2777058707 @default.
• W4231945484 hasConcept C2777701055 @default.
• W4231945484 hasConcept C2779338263 @default.
• W4231945484 hasConcept C2780653079 @default.
• W4231945484 hasConcept C31760486 @default.
• W4231945484 hasConcept C535046627 @default.
• W4231945484 hasConcept C71924100 @default.
• W4231945484 hasConcept C87355193 @default.
• W4231945484 hasConcept C90924648 @default.
• W4231945484 hasConceptScore W4231945484C121332964 @default.
• W4231945484 hasConceptScore W4231945484C121608353 @default.
• W4231945484 hasConceptScore W4231945484C126322002 @default.
• W4231945484 hasConceptScore W4231945484C142424586 @default.
• W4231945484 hasConceptScore W4231945484C143998085 @default.
• W4231945484 hasConceptScore W4231945484C203014093 @default.
• W4231945484 hasConceptScore W4231945484C2777058707 @default.
• W4231945484 hasConceptScore W4231945484C2777701055 @default.
• W4231945484 hasConceptScore W4231945484C2779338263 @default.
• W4231945484 hasConceptScore W4231945484C2780653079 @default.
• W4231945484 hasConceptScore W4231945484C31760486 @default.
• W4231945484 hasConceptScore W4231945484C535046627 @default.
• W4231945484 hasConceptScore W4231945484C71924100 @default.
• W4231945484 hasConceptScore W4231945484C87355193 @default.
• W4231945484 hasConceptScore W4231945484C90924648 @default.
• W4231945484 hasIssue "14_suppl" @default.
• W4231945484 hasLocation W42319454841 @default.
• W4231945484 hasOpenAccess W4231945484 @default.
• W4231945484 hasPrimaryLocation W42319454841 @default.
• W4231945484 hasRelatedWork W1970884884 @default.
• W4231945484 hasRelatedWork W2020184844 @default.
• W4231945484 hasRelatedWork W2043813787 @default.
• W4231945484 hasRelatedWork W2073341443 @default.
• W4231945484 hasRelatedWork W2081460859 @default.
• W4231945484 hasRelatedWork W2103810091 @default.
• W4231945484 hasRelatedWork W2414380992 @default.
• W4231945484 hasRelatedWork W2567198968 @default.
• W4231945484 hasRelatedWork W2612992549 @default.
• W4231945484 hasRelatedWork W3152050855 @default.
• W4231945484 hasVolume "22" @default.
• W4231945484 isParatext "false" @default.
• W4231945484 isRetracted "false" @default.
• W4231945484 workType "article" @default.